The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis

OBJECTIVE: Secukinumab, a new treatment agent, selectively neutralizes interleukin (IL)-17A. It is used in the treatment of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis. It is known that the agents used in the treatment of rheumatic diseases have effects on hematological par...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Rheumatol
Autori principali: Karataş, Ahmet, Gerçek, Aybüke Nisa, Öz, Burak, Gözel, Nevzat, Pişkin Sağır, Rabia, Gür, Mustafa, Koca, Süleyman Serdar
Natura: Artigo
Lingua:Inglês
Pubblicazione: Medical Research and Education Association 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574766/
https://ncbi.nlm.nih.gov/pubmed/32910771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/eurjrheum.2020.20109
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi